First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Atrial Fibrillation
Interventions
DRUG

Anti Arrhythmics

Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone

PROCEDURE

Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation

Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins

Trial Locations (5)

10461

Montefiore Medical Center, The Bronx

19104

Penn Presbyterian Medical Center, Philadelphia

University of Pennsylvania, Philadelphia

44109

MetroHealth, Cleveland

84724

University of Arizona, Tucson

All Listed Sponsors
collaborator

Biosense Webster, Inc.

INDUSTRY

collaborator

Texas Cardiac Arrhythmia Research Foundation

OTHER

lead

University of Pennsylvania

OTHER

NCT04037397 - First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3) | Biotech Hunter | Biotech Hunter